Adjuvant for desensitization vaccine and novel desensitization vaccine

A vaccine and desensitization technology, applied to allergic diseases, medical preparations containing active ingredients, allergen antigen components, etc., can solve the problems of inability to induce immune tolerance, and achieve rapid induction of peripheral immune tolerance, Rapid desensitization effect, enhanced effect of anti-allergy immunotherapy

Active Publication Date: 2018-06-01
CHENGDU MAXVAX BIOTECHNOLOGY LLC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chen Dexiang and others published a paper in the journal "Clinical Immunology of Allergy", proving that common adjuvants for vaccines to prevent infectious diseases, such as CpG gene sequences, can stimulate inflammation at the injection site and promote the maturation of antigen-presenting cells, but cannot induce immune resistance. by

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adjuvant for desensitization vaccine and novel desensitization vaccine
  • Adjuvant for desensitization vaccine and novel desensitization vaccine
  • Adjuvant for desensitization vaccine and novel desensitization vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] The desensitization vaccine formula in Example 1 contains glucocorticoid (dexamethasone acetate) and egg white albumin. Applying the vaccine locally to the skin can inhibit the production of inflammatory cytokines in skin cells. Such as figure 1 Shown are the levels of pro-inflammatory cytokines produced by the skin at the site of application. In Example 1, the administration of the desensitization treatment group contained egg white albumin and glucocorticoid; the administration of the standard treatment group only contained egg white albumin; the administration of the untreated group was physiological saline.

[0051] The experiments of Example 1 used 6 to 8 week old female Balb / c mice. The abdominal skin of the mice was shaved and rested for 24 hours. For mice in desensitization treatment group, apply glucocorticoid (0.1% ointment) to the depilated skin; the next day, apply egg white albumin liquid to the surface layer of skin at the same site with a cotton ball - ...

Embodiment 2

[0056] Example 2 establishes dust mite allergy and desensitization treatment models in mice.

[0057] Six to eight week old female C57BL / 6 mice (Charles River, Wilmington, MA) or Balb / c mice (Charles River) were used in this experiment. The mouse allergy model involves two steps: sensitization and challenge. The sensitization step was to intraperitoneally inject 50 μg of house dust mite extract (adsorbed on the surface of 1 mg of aluminum hydroxide) to mice. The injection volume is 0.5 ml. Attack virus after 14 days. The challenge step is to spray 10 μg HDM (HDM is dust mite extract) into the lungs of the mouse trachea. 48 hours in repeated attack once. Twenty-four hours after the second challenge, mice were euthanized using carbon dioxide. Bronchoalveolar lavage fluid (BALF) was collected for cell counting and cytokine analysis, and lung tissue was collected for section staining.

[0058] After the death of the mice, the lungs were flushed 3 times with 1 ml of sterile s...

Embodiment 3

[0061] In Example 3, the desensitization vaccine containing glucocorticoids and house dust mite extract was used to treat the allergic symptoms of the sensitized mice obtained in Embodiment 2 by immunotherapy, which effectively reduced the respiratory inflammation of the mice induced by dust mite. Such as figure 2 Shown is the effect of desensitization treatment on pulmonary invading eosinophils in a mouse model of dust mites. The administration of desensitization treatment group contained dust mite extract allergen and glucocorticoid, the administration of standard treatment group only contained dust mite extract, and the administration of untreated group was normal saline. Using a desensitizing vaccine containing glucocorticoids and standardized extracts of house dust mite, immunotherapy reduced airway inflammation in mice, especially the reduction in the number of eosinophils in the lungs. image 3 Shown is the effect of desensitization treatment on cytokines in the lung ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an adjuvant for a desensitization vaccine; the adjuvant is prepared from components with immune tolerance; the components with immune tolerance are anti-inflammatory compounds.The invention also provides the novel desensitization vaccine using the anti-inflammatory compounds as the adjuvant. The anti-inflammatory compounds are used as the adjuvant and are co-injected with an allergen, so that inflammation of allergy vaccines is prevented at the injection site; the anti-inflammatory compounds have an effect of inhibiting the maturation of antigen-presenting cells; the anti-inflammatory compounds directly act on the antigen-presenting cells so as to inhibit the antigen-presenting cells from becoming mature cells during antigen uptake and presentation; the anti-inflammatory compounds realizes long-acting treatment of allergies by rapidly inducing the production of Treg cells. The desensitization vaccine provided by the invention can realize rapid, long-acting and effective treatment on the allergies from the view of sensitization mechanism.

Description

technical field [0001] The present invention relates to a vaccine and its adjuvant, in particular to a desensitized vaccine and its adjuvant Background technique [0002] Allergies are hypersensitivity reactions of the immune system to harmless substances in the environment. Common causes of allergies include house dust mites, plant pollen, mold, drugs, food, animal dander, and insect venom. Immunotherapy can provide long-term relief of symptoms, prevent the development of diseases ranging from rhinitis to allergic asthma, and even cure them. The process of allergy occurrence includes the sensitization stage and the allergic reaction stage. In the sensitization stage, when the body comes into contact with allergens for the first time, an immune response occurs, thereby producing a large number of type 2 T helper lymphocytes (T helper 2, Th2) and IgE antibodies to specific allergens. IgE antibodies bind to receptors on the surface of chief cells and basophils in the mucous...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K45/00A61K31/573A61K39/35A61K39/36A61P37/08
CPCA61K31/573A61K39/35A61K39/36A61K39/39A61K45/00A61K2039/55511
Inventor 陈德祥董丽春
Owner CHENGDU MAXVAX BIOTECHNOLOGY LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap